Orthopedic pain
Image
| Diclofenac is suitable for the treatment of acute painful and inflammatory conditions.1
Diclofenac exerts its therapeutic effect through the inhibition of cyclooxygenase (COX), which inhibits prostaglandin production whose synergistic interactions with other mediators promote local inflammatory reactions and hyperalgesia.2 Traditionally, two isoforms of COX are known, COX-1 and COX-2, on which diclofenac has inhibitory effects.2 |
Image
| Tailored treatment for your patients
Chronic pain is an ongoing issue in the community and takes a heavy toll on the healthcare system, in some part due to a lack of efficacy from existing treatments.3 Analgesics (eg, paracetamol, codeine and other opiate-like drugs); oral or topical non-steroidal anti-inflammatory drugs (NSAIDs); intra articular injections, for example, with glucocorticoids; and occasionally also agents for neuropathic pain.5 The evidence for pharmacological pain treatment was not part of the current review but has been evaluated by other task forces.4 Analgesics with a rapid onset of pain relief are often the preferred treatment option in acute pain conditions.5
|
Our Products
References
Cataflam® 50mg Egyptian Drug Authority approved insert leaflet. Date of approval: 26/12/2024.
Akbulut N, Üstüner E, Atakan C, etal. Comparison of the effect of naproxen, etodolac and diclofenac on postoperative sequels following third molar surgery: a randomised, double-blind, crossover study. Med Oral Patol Oral Cir Bucal. 2014;19(2):e149-56.
Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287-333.
Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797-807.
Hofele CM, Gyenes V, Daems LN, et al. Efficacy and tolerability of diclofenac potassium sachets in acute postoperative dental pain: a placebo-controlled, randomised, comparative study vs. diclofenac potassium tablets. Int J Clin Pract. 2006;60(3):300-7.
Approved by Egyptian Drug Authority: HF0082OA4734/092025. Invalidation date: 01/09/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg
Image
|
HF0082OA4734/092025 |
Adverse Events Reporting We encourage using the following Electronic reporting tool for reporting into the safety database directly: |